fuente:[1] Takeda Pharmaceutical Company Limited (TAK) Morgan Stanley 23rd Annual Global Transcript (https://seekingalpha.com/article/4820691-take ...)[2] Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress | Nasdaq (https://www.nasdaq.com/press-release/takeda-a ...)[3] Top 10 most anticipated drug launches of 2025 - Fierce Pharma (https://www.fiercepharma.com/pharma/top-10-mo ...)